Abstract
Background: Androgen-deprivation therapy (ADT) is an important component of prostate cancer treatment, as an adjuvant in intermediate to high-risk localised disease, or for the treatment of metastatic or locally advanced/recurrent prostate cancer. Gonadotropin releasing hormone (GnRH) agonists are a commonly-prescribed form of ADT. GnRH agonist use for prostate cancer has been associated in a few cases with stimulation of the growth of meningiomas, which are the most common intracerebral tumours and which commonly harbour various hormone receptors, including those for GnRH, progesterone and oestrogen. To our knowledge, cranial nerve palsies have not previously been described after GnRH treatment in humans.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
